468
Views
4
CrossRef citations to date
0
Altmetric
Report

Inhibiting mitochondrial-dependent proteolysis of Mcl-1 promotes resistance to DNA damage

, &
Pages 88-98 | Received 13 Sep 2011, Accepted 13 Oct 2011, Published online: 01 Jan 2012
 

Abstract

Elimination of Myeloid Leukemia Cell 1 (Mcl-1) is an early event in the onset of cell death following DNA damage and in many settings plays a critical role in dictating the success of chemotherapeutic agents. Following DNA damage, Mcl-1 is rapidly and efficiently targeted to the 26S proteasome through the action of E3 ubiquitin ligases. Tumors having acquired lesions that lead to stabilization of Mcl-1 are highly aggressive and have a poorer prognosis. Herein, we further characterize an additional mechanism of Mcl-1 proteolysis that is proteasome-independent but mitochondrial-dependent. A mitochondrial targeting signal located in the N-terminus of Mcl-1 is essential for targeting Mcl-1 to this alternative degradative avenue. We demonstrate that the Akt/mTORC1 survival pathway protects Mcl-1 from mitochondrial-dependent proteolysis. Disrupting Mcl-1 mitochondrial targeting improves the pro-survival capacity of Mcl-1 both ex vivo and in vivo in the well characterized mouse Eμ-Myc lymphoma model. Our data uncover an important relationship between the mitochondria and the Mcl-1 N-terminus in dictating cell fate following DNA damage.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.